Purpose: Ceritinib 750 mg/day was approved for the treatment of patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) based on ASCEND-4 study. The objective of this article is to introduce the use of time-dependent modeling approach in the updated exposure-efficacy analysis of ceritinib for the first-line indication. READ ARTICLE
Cancer Chemotherapy and Pharmacology DOI:10.1007/s00280-019-03830-5
Authors: Yvonne Y Lau, Wen Gu, Yu-Yun Ho, Ying Hong, Xinrui Zhang and Patrick Urban
